Matthew D Hellmann
Overview
Explore the profile of Matthew D Hellmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
171
Citations
41759
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2025 Feb;
639(8054):E19.
PMID: 40016449
No abstract available.
2.
Robles-Oteiza C, Hastings K, Choi J, Sirois I, Ravi A, Exposito F, et al.
J Exp Med
. 2024 Nov;
222(1.
PMID: 39585348
Despite the established use of immune checkpoint inhibitors (ICIs) to treat non-small cell lung cancer (NSCLC), only a subset of patients benefit from treatment and ∼50% of patients whose tumors...
3.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2024 Oct;
635(8038):462-471.
PMID: 39385035
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of...
4.
Elkrief A, Montesion M, Sivakumar S, Hale C, Bowman A, Bektas A, et al.
J Clin Oncol
. 2024 Jul;
42(28):3339-3349.
PMID: 39038258
PURPOSEThe impact of the intratumoral microbiome on immune checkpoint inhibitor (ICI) efficacy in patients with non-small-cell lung cancer (NSCLC) is unknown. Preclinically, intratumoral Escherichia is associated with a proinflammatory tumor...
5.
Elkrief A, Mendez-Salazar E, Maillou J, Vanderbilt C, Gogia P, Desilets A, et al.
NPJ Precis Oncol
. 2024 Jul;
8(1):143.
PMID: 39014160
Anti-PD(L)-1 inhibition combined with platinum doublet chemotherapy (Chemo-IO) has become the most frequently used standard of care regimen in patients with non-small cell lung cancer (NSCLC). The negative impact of...
6.
Espinosa-Carrasco G, Chiu E, Scrivo A, Zumbo P, Dave A, Betel D, et al.
Cancer Cell
. 2024 Jun;
42(7):1202-1216.e8.
PMID: 38906155
Tumor-specific CD8 T cells are frequently dysfunctional and unable to halt tumor growth. We investigated whether tumor-specific CD4 T cells can be enlisted to overcome CD8 T cell dysfunction within...
7.
Patel S, Alonso-Gordoa T, Banerjee S, Wang D, Naidoo J, Standifer N, et al.
J Immunother Cancer
. 2024 Feb;
12(2).
PMID: 38309722
Background: The combination of monalizumab (anti-NKG2A/CD94) and durvalumab (anti-programmed death ligand-1) may promote antitumor immunity by targeting innate and adaptive immunity. This phase 1/2 study of monalizumab and durvalumab evaluated...
8.
Memon D, Schoenfeld A, Ye D, Fromm G, Rizvi H, Zhang X, et al.
Cancer Cell
. 2024 Jan;
42(2):209-224.e9.
PMID: 38215748
Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired...
9.
Elkrief A, Waters N, Smith N, Dai A, Slingerland J, Aleynick N, et al.
Cancer Immunol Res
. 2023 Dec;
12(3):308-321.
PMID: 38108398
Colitis induced by treatment with immune-checkpoint inhibitors (ICI), termed irColitis, is a substantial cause of morbidity complicating cancer treatment. We hypothesized that abnormal fecal microbiome features would be present at...
10.
Elkrief A, Riccuiti B, Alessi J, Fei T, Kalvin H, Egger J, et al.
Oncologist
. 2023 Aug;
28(11):978-985.
PMID: 37589215
Background: Direct KRASG12C inhibitors are approved for patients with non-small cell lung cancers (NSCLC) in the second-line setting. The standard-of-care for initial treatment remains immune checkpoint inhibitors, commonly in combination...